SCHEMBL4308023

SCHEMBL4308023

O=C(OC(COc1ccccc1Cl)Cn1ncnn1)N1CCC(Cc2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 12/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ATM Q13315 1/20 0.38
FAAH O00519 1/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
HTR2B P41595 1/20 0.36
MAPK14 Q16539 1/20 0.36
DRD4 P21917 1/20 0.35
GRIN2B Q13224 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4304826 0.92 MEN1 (0.48) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL4314093 0.91 CCR3 (0.37) CCR3MEN1KMT2AATMCYP1A2
SCHEMBL4306625 0.90 CCR3 (0.39) CCR3MEN1KMT2ADRD4
SCHEMBL4308566 0.84 CCR3 (0.42) CCR3MEN1KMT2AFAAHCYP2C9
SCHEMBL4313000 0.83 CCR3 (0.43) CCR3MEN1KMT2AFAAHCYP2C9
SCHEMBL4311328 0.81 CCR3 (0.41) CCR3FAAH
SCHEMBL4308692 0.80 DRD4 (0.52) MEN1KMT2ASMN1; SMN2FAAHDRD4
SCHEMBL4306525 0.79 CCR3 (0.40) CCR3MEN1KMT2AFAAH
SCHEMBL4311339 0.79 SPR (0.43) MEN1KMT2AALDH1A1SMN1; SMN2FAAH
SCHEMBL4309687 0.78 CCR3 (0.39) CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879873-B1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK BIOPHARMACEUTICALS CO LTD (KR) 2013-10-09 EP disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
US-7598279-B2 Neurotherapeutic azole compounds SK HOLDINGS CO., LTD. (KR) 2009-10-06 US disclosed
EP-1879873-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK Holdings Co., Ltd. (KR) 2008-01-23 EP disclosed
US-20060258718-A1 Neurotherapeutic azole compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2006-11-16 US disclosed
WO-2006112685-A1 NEUROTHERAPEUTIC AZOLE COMPOUNDS SK HOLDINGS CO., LTD. (KR) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258718-A1 Neurotherapeutic azole compounds CHRNA10, CHRNA4, CHRNA3 CCR3 3607/4885MEN1 1549/4885KMT2A 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.